citalopram has been researched along with Amentia in 36 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Excerpt | Relevance | Reference |
---|---|---|
"To assess efficacy and safety of citalopram compared to quetiapine and olanzapine for the treatment of agitation in patients with Alzheimer disease (AD)." | 9.24 | Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. ( Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017) |
"The aim was to determine the relationship between (R) and (S)-citalopram enantiomer exposure (AUC(0,24 h)) and therapeutic response in agitated individuals greater than 60 years old with Alzheimer's dementia (AD)." | 9.22 | R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. ( Bies, R; Devanand, DP; Drye, LT; Ho, T; Lyketsos, C; Mintzer, JE; Mulsant, BH; Munro, CA; Pollock, BG; Porsteinsson, AP; Schantz, O; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
"This study examined the potential of an antidepressant drug, escitalopram, to improve depression, resilience to stress, and quality of life in family dementia caregivers in a randomized placebo-controlled double-blinded trial." | 9.14 | Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. ( Irwin, MR; Lavretsky, H; Siddarth, P, 2010) |
"To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation." | 9.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
" This randomised, double-blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia." | 9.09 | A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. ( Augusto De Mendonça Lima, C; Eglin, M; Godderis, J; Karlsson, I; Nygaard, H; Simányi, M; Taal, M, 2000) |
"A total of 149 patients in 7 centers in Denmark, Norway and Sweden entered a 6-week double-blind trial intended to assess the antidepressant effect and safety of citalopram vs placebo in depressed elderly patients (65 years of age or older) who might also suffer from somatic disorders and/or senile dementia." | 9.07 | A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. ( Eriksson, S; Gottfries, CG; Gylding-Sabroe, J; Kristensen, M; Lyby, K; Nyth, AL; Ofsti, E; Refsum, HE; Smedegaard-Andersen, L; Syversen, S, 1992) |
" This report describes a patient with PDD who developed deep venous thrombosis (DVT) and hyponatremia after initiating citalopram treatment." | 8.31 | Deep venous thrombosis and hyponatremia associated with citalopram use for behavioral symptoms in Parkinson's disease: a case report. ( Albalawi, A, 2023) |
"to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia." | 7.81 | [Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015) |
"To assess efficacy and safety of citalopram compared to quetiapine and olanzapine for the treatment of agitation in patients with Alzheimer disease (AD)." | 5.24 | Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. ( Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017) |
"The aim was to determine the relationship between (R) and (S)-citalopram enantiomer exposure (AUC(0,24 h)) and therapeutic response in agitated individuals greater than 60 years old with Alzheimer's dementia (AD)." | 5.22 | R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. ( Bies, R; Devanand, DP; Drye, LT; Ho, T; Lyketsos, C; Mintzer, JE; Mulsant, BH; Munro, CA; Pollock, BG; Porsteinsson, AP; Schantz, O; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
"This study examined the potential of an antidepressant drug, escitalopram, to improve depression, resilience to stress, and quality of life in family dementia caregivers in a randomized placebo-controlled double-blinded trial." | 5.14 | Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. ( Irwin, MR; Lavretsky, H; Siddarth, P, 2010) |
"To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation." | 5.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
" This randomised, double-blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia." | 5.09 | A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. ( Augusto De Mendonça Lima, C; Eglin, M; Godderis, J; Karlsson, I; Nygaard, H; Simányi, M; Taal, M, 2000) |
"A total of 149 patients in 7 centers in Denmark, Norway and Sweden entered a 6-week double-blind trial intended to assess the antidepressant effect and safety of citalopram vs placebo in depressed elderly patients (65 years of age or older) who might also suffer from somatic disorders and/or senile dementia." | 5.07 | A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. ( Eriksson, S; Gottfries, CG; Gylding-Sabroe, J; Kristensen, M; Lyby, K; Nyth, AL; Ofsti, E; Refsum, HE; Smedegaard-Andersen, L; Syversen, S, 1992) |
"Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia." | 4.87 | Antidepressants for agitation and psychosis in dementia. ( Adunuri, N; Gill, SS; Gruneir, A; Herrmann, N; Rochon, P; Seitz, DP, 2011) |
" This report describes a patient with PDD who developed deep venous thrombosis (DVT) and hyponatremia after initiating citalopram treatment." | 4.31 | Deep venous thrombosis and hyponatremia associated with citalopram use for behavioral symptoms in Parkinson's disease: a case report. ( Albalawi, A, 2023) |
"Long-term treatment with tricyclic antidepressants, Hypericum perforatum, or escitalopram may be associated with reduced incidence of dementia." | 3.96 | To Be Continued? Long-Term Treatment Effects of Antidepressant Drug Classes and Individual Antidepressants on the Risk of Developing Dementia: A German Case-Control Study. ( Bartels, C; Belz, M; Bohlken, J; Hessmann, P; Kostev, K; Vogelgsang, J; Wiltfang, J, 2020) |
"to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia." | 3.81 | [Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015) |
"An open, multi-centre study was designed to address the effectiveness and tolerability profile of treatment with escitalopram under naturalistic conditions, in elderly outpatients (above 65 years of age) with depression." | 3.76 | Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany. ( Flürenbrock, W; Möller, HJ; Schnitker, J, 2010) |
" Dosing strategies, discontinuation considerations, and side effects are discussed." | 2.72 | The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia. ( Chen, A; Cloutier, A; Copeli, F; Metzger, E; Osser, DN, 2021) |
"Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients." | 2.70 | Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. ( Bharucha, A; Chew, ML; Huber, KA; Jacob, NJ; Kastango, KB; Marin, R; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J; Sweet, RA, 2002) |
"Citalopram is a selective serotonin re-uptake inhibitor that has demonstrated antidepressant efficacy in numerous controlled clinical trials." | 2.41 | Citalopram: a comprehensive review. ( Pollock, BG, 2001) |
"Depression is a highly prevalent concomitant of dementia." | 2.40 | Depression and dementia: comorbidities, identification, and treatment. ( Meyers, BS, 1998) |
"Citalopram is an SSRI drug with an attractive pharmacokinetic profile, i." | 2.39 | Scandinavian experience with citalopram in the elderly. ( Gottfries, CG, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (22.22) | 18.2507 |
2000's | 7 (19.44) | 29.6817 |
2010's | 16 (44.44) | 24.3611 |
2020's | 5 (13.89) | 2.80 |
Authors | Studies |
---|---|
Bucki, A | 1 |
Marcinkowska, M | 1 |
Śniecikowska, J | 1 |
Więckowski, K | 1 |
Pawłowski, M | 1 |
Głuch-Lutwin, M | 1 |
Gryboś, A | 1 |
Siwek, A | 1 |
Pytka, K | 1 |
Jastrzębska-Więsek, M | 1 |
Partyka, A | 1 |
Wesołowska, A | 1 |
Mierzejewski, P | 1 |
Kołaczkowski, M | 1 |
Fischer, CE | 3 |
Namasivayam, A | 3 |
Crawford-Holland, L | 3 |
Hakobyan, N | 3 |
Schweizer, TA | 3 |
Munoz, DG | 3 |
Pollock, BG | 11 |
Albalawi, A | 1 |
Bartels, C | 1 |
Belz, M | 1 |
Vogelgsang, J | 1 |
Hessmann, P | 1 |
Bohlken, J | 1 |
Wiltfang, J | 1 |
Kostev, K | 1 |
Chen, A | 1 |
Copeli, F | 1 |
Metzger, E | 1 |
Cloutier, A | 1 |
Osser, DN | 1 |
Smith, GS | 1 |
Kuwabara, H | 1 |
Nandi, A | 1 |
Gould, NF | 1 |
Nassery, N | 1 |
Savonenko, A | 1 |
Joo, JH | 1 |
Kraut, M | 1 |
Brasic, J | 1 |
Holt, DP | 1 |
Hall, AW | 1 |
Mathews, WB | 1 |
Dannals, RF | 1 |
Avramopoulos, D | 1 |
Workman, CI | 1 |
Viscogliosi, G | 1 |
Chiriac, IM | 1 |
Ettorre, E | 1 |
Rubin, R | 1 |
Koenig, AM | 1 |
Butters, MA | 1 |
Begley, A | 1 |
Ogbagaber, S | 1 |
Wahed, AS | 1 |
Reynolds, CF | 1 |
Kotbi, N | 1 |
Singh, A | 1 |
Kneifati-Hayek, J | 1 |
Odom, A | 1 |
Alexopoulos, G | 1 |
Zhitkova, JV | 1 |
Wilkins, JM | 1 |
Forester, BP | 1 |
Ho, T | 1 |
Mulsant, BH | 6 |
Schantz, O | 1 |
Devanand, DP | 1 |
Mintzer, JE | 1 |
Porsteinsson, AP | 1 |
Schneider, LS | 1 |
Weintraub, D | 1 |
Yesavage, J | 1 |
Drye, LT | 1 |
Munro, CA | 1 |
Shade, DM | 1 |
Lyketsos, C | 1 |
Bies, R | 1 |
Ozturk, A | 1 |
Yasar, H | 1 |
Gulsun, M | 1 |
Balıkcı, A | 1 |
Bozoglu, E | 1 |
Naharcı, MI | 1 |
Boyraz, O | 1 |
Oztın, H | 1 |
Doruk, H | 1 |
Dombrovski, AY | 1 |
Ferrell, RE | 1 |
Lotrich, FE | 1 |
Rosen, JI | 1 |
Wallace, M | 1 |
Houck, PR | 3 |
Mazumdar, S | 4 |
Lavretsky, H | 1 |
Siddarth, P | 1 |
Irwin, MR | 1 |
Möller, HJ | 1 |
Schnitker, J | 1 |
Flürenbrock, W | 1 |
Seitz, DP | 1 |
Adunuri, N | 1 |
Gill, SS | 1 |
Gruneir, A | 1 |
Herrmann, N | 1 |
Rochon, P | 1 |
Tremolizzo, L | 1 |
Fermi, S | 1 |
Fusco, ML | 1 |
Susani, E | 1 |
Frigo, M | 1 |
Piolti, R | 1 |
Ferrarese, C | 1 |
Appollonio, I | 1 |
Ismail, Z | 1 |
Emeremni, CA | 1 |
Rosen, J | 3 |
Rajji, TK | 1 |
Schölzel-Dorenbos, CJ | 1 |
Blakesley, RE | 1 |
Huber, KA | 2 |
Leblhuber, F | 1 |
Gottfries, CG | 4 |
Ragneskog, H | 1 |
Eriksson, S | 3 |
Karlsson, I | 3 |
Soares, JC | 1 |
Gershon, S | 1 |
Meyers, BS | 1 |
Godderis, J | 1 |
Augusto De Mendonça Lima, C | 1 |
Nygaard, H | 1 |
Simányi, M | 1 |
Taal, M | 1 |
Eglin, M | 1 |
Kim, KY | 1 |
Bader, GM | 1 |
Jones, E | 1 |
Spigset, O | 1 |
Wilhelmsson, C | 1 |
Mjörndal, T | 1 |
Sweet, RA | 1 |
Bharucha, A | 1 |
Marin, R | 1 |
Jacob, NJ | 1 |
Kastango, KB | 1 |
Chew, ML | 1 |
Nyth, AL | 2 |
Lyby, K | 1 |
Smedegaard-Andersen, L | 1 |
Gylding-Sabroe, J | 1 |
Kristensen, M | 1 |
Refsum, HE | 1 |
Ofsti, E | 1 |
Syversen, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Caring for Caregivers With Mind-body Exercise[NCT04019301] | 47 participants (Actual) | Interventional | 2019-04-22 | Active, not recruiting | |||
Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients[NCT01119638] | Phase 4 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
Study to Determine Steady-state Level of Citalopram Pharmacokinetic Parameters in Patients With Short Bowel Syndrome[NCT00876226] | 0 participants (Actual) | Interventional | 2010-05-01 | Withdrawn | |||
Continuation Pharmacotherapy for Agitation of Dementia[NCT00073658] | Phase 2 | 137 participants | Interventional | 2000-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
10 reviews available for citalopram and Amentia
Article | Year |
---|---|
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Topics: Aged; Antipsychotic Agents; Citalopram; Dementia; Humans; Psychotic Disorders; Schizophrenia | 2022 |
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Topics: Academic Medical Centers; Aged; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazol | 2021 |
Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia.
Topics: Antipsychotic Agents; Caregivers; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Dis | 2016 |
Antidepressants for agitation and psychosis in dementia.
Topics: Adult; Antidepressive Agents; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Disorde | 2011 |
Scandinavian experience with citalopram in the elderly.
Topics: Age Factors; Aged; Antidepressive Agents; Citalopram; Dementia; Depressive Disorder; Dopamine; Human | 1996 |
Therapeutic targets in late-life psychoses: review of concepts and critical issues.
Topics: Affective Disorders, Psychotic; Age Factors; Age of Onset; Aged; Antipsychotic Agents; Benzodiazepin | 1997 |
Depression and dementia: comorbidities, identification, and treatment.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Benzamides; Citalopram; Clomipramine; Cog | 1998 |
Behavioral disturbances of dementia.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antipsychotic Agents; Basal Ganglia Diseases; Behavioral S | 1998 |
Citalopram: a comprehensive review.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Clinical Trials | 2001 |
Treatment of depression in elderly patients with and without dementia disorders.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia; Dementia, Vascular; Depressive Disorder; Humans; Neur | 1992 |
11 trials available for citalopram and Amentia
Article | Year |
---|---|
Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; | 2017 |
R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia; Female; Humans; Isomerism; Male; Psychiatric Status R | 2016 |
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.
Topics: Aged; Aged, 80 and over; Alleles; Antipsychotic Agents; Behavioral Symptoms; Citalopram; Dementia; F | 2010 |
Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Caregivers; Citalopram; | 2010 |
A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
Topics: Aged, 80 and over; Citalopram; Dementia; Double-Blind Method; Female; Humans; Male; Psychiatric Stat | 2013 |
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Topics: Aged, 80 and over; Antipsychotic Agents; Citalopram; Dementia; Double-Blind Method; Female; Hospital | 2007 |
[Citalopram in treatment of behavioral disorders in demented patients].
Topics: Affective Symptoms; Aged; Aged, 80 and over; Alzheimer Disease; Citalopram; Dementia; Double-Blind M | 1994 |
A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Dementia; Depressive | 2000 |
Low serum sodium concentrations during treatment with citalopram in elderly patients: relationship to serum citalopram levels and to platelet serotonin 5-HT2A receptor status.
Topics: Aged; Aged, 80 and over; Blood Platelets; Citalopram; Dementia; Electrolytes; Female; Humans; Male; | 2000 |
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavioral Symptoms; Citalopram; Dementia; Donepezil; | 2002 |
A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia.
Topics: Aged; Citalopram; Cognition; Dementia; Depressive Disorder; Double-Blind Method; Humans; Placebos | 1992 |
15 other studies available for citalopram and Amentia
Article | Year |
---|---|
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
Topics: Affect; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Dementia; Dopamine Agonist | 2017 |
Deep venous thrombosis and hyponatremia associated with citalopram use for behavioral symptoms in Parkinson's disease: a case report.
Topics: Aged; Aged, 80 and over; Behavioral Symptoms; Citalopram; Dementia; Female; Humans; Hyponatremia; Pa | 2023 |
To Be Continued? Long-Term Treatment Effects of Antidepressant Drug Classes and Individual Antidepressants on the Risk of Developing Dementia: A German Case-Control Study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Case-Control Studi | 2020 |
Molecular imaging of beta-amyloid deposition in late-life depression.
Topics: Age Factors; Aged; Alzheimer Disease; Amyloid beta-Peptides; Antidepressive Agents, Second-Generatio | 2021 |
Exploring the Relationship Between Depression and Dementia.
Topics: Adult; Aged, 80 and over; Antidepressive Agents; Citalopram; Cognitive Dysfunction; Dementia; Depres | 2018 |
Commentary on "When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram".
Topics: Alzheimer Disease; Anxiety; Citalopram; Dementia; Humans; Psychomotor Agitation | 2019 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysf | 2014 |
Citalopram in agitated and delusional demented patients who failed treatment with antipsychotic agents.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Delus | 2014 |
[Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia].
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Chronic Disease; Citalopram; Cogniti | 2015 |
Remission in visual hallucinatory experiences after citalopram treatment in a patient with dementia.
Topics: Citalopram; Dementia; Hallucinations; Humans; Remission Induction | 2017 |
Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Citalopram; Dementia; Depression; Depressive Disorder; De | 2010 |
Generalized action myoclonus associated with escitalopram in a patient with mixed dementia.
Topics: Aged; Citalopram; Dementia; Depression; Female; Humans; Myoclonus | 2011 |
Mild behavioral impairment: a prodromal stage of frontotemporal lobar degeneration.
Topics: Brain; Citalopram; Dementia; Diagnosis, Differential; Humans; Male; Middle Aged; Neuropsychological | 2006 |
Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Antidepressive Agents; Anxiety Disorders; Citalopram; C | 1996 |
Citalopram for verbal agitation in patients with dementia.
Topics: Citalopram; Dementia; Humans; Long-Term Care; Male; Middle Aged; Psychomotor Agitation; Selective Se | 2000 |